---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-26-001634"
form_type: "8-K"
ticker: "NXL"
cik: "0001527352"
company_name: "Nexalin Technology, Inc."
filed_at: "2026-02-25T23:59:59+00:00"
generated_at: "2026-05-16T00:16:17.965374+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nexalin announces pivotal HALO Clarity trial for insomnia to support FDA de novo submission

## Summary
- 150-patient, triple-blinded, sham-controlled randomized study via decentralized NeuroCare virtual clinic with Lindus Health.
- Designed to support planned FDA de novo submission for moderate to severe insomnia treatment.
- Builds on prior published 120-patient study showing significant sleep improvements with no adverse effects.
- Targets $multi-billion insomnia market; ~30M U.S. adults seek drug-free options.

## SEC filing metadata
- accession: 0001829126-26-001634
- form_type: 8-K
- ticker: NXL
- cik: 0001527352
- company_name: Nexalin Technology, Inc.
- filed_at: 2026-02-25T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527352/000182912626001634/0001829126-26-001634-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527352/000182912626001634/nexalintec_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-26-001634
- JSON: https://secwatch.observer/filing/0001829126-26-001634.json
- Plain text: https://secwatch.observer/filing/0001829126-26-001634.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.